Will the FDA approve camizestrant for advanced breast cancer?

1.0 puan (24s)Health & MedicineOne-Off2ay

KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiKabaca kalibre

Güncel ima edilen olasılık

Before Jan 1, 2028 77%

5 seçenek arasında lider

Piyasa kalitesi

45 / 100

Düşük kalite

24s Hacim

₺2,5 B

Likidite

₺211,2 B

Orta likidite

Alis / Satis

32.0% / 37.0%

Spread

5.0 pt

Orta spread

Piyasa verileri

16 dakika önce guncellendi

14 May 26 2:001 Eki 26 3:59

Trendler

Sonuç24sOlasılık

Yalnızca sanal bakiye, gerçek para yokYatırım tavsiyesi değildir

Seçilen sonuç

Before Oct 1, 202637%

Tutar (USDT)

Kurallar

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Hacim trendi

$53

2 Tem14g veri28 Tem

İlgili Piyasalar

Will the FDA approve MDMA for PTSD?

₺0

Before Jan 1, 2027: 10%

KALSHI

Hantavirus pandemic in 2026?

₺5,3 Mn

Evet: 3%

POLYMARKET

# of views of MrBeast video day 3?

₺352,7 B

26-27M: 73%

POLYMARKET

New pandemic in 2026?

₺280,5 B

Evet: 9%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Bu konularda aktif

BitcoinBTC$63,480.41-3.05%

EthereumETH$1,881.56-4.27%

SolanaSOL$73.34-4.36%

DogecoinDOGE$0.07-4.13%

XRPXRP$1.06-4.87%

BNBBNB$564.93-1.71%

İlgili Haberler

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Kurallar

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Will the FDA approve camizestrant for advanced breast cancer?

1.0 puan (24s)Health & MedicineOne-Off2ay

KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiKabaca kalibre

Güncel ima edilen olasılık

Before Jan 1, 2028 77%

5 seçenek arasında lider

Piyasa kalitesi

45 / 100

Düşük kalite

24s Hacim

₺2,5 B

Likidite

₺211,2 B

Orta likidite

Alis / Satis

32.0% / 37.0%

Spread

5.0 pt

Orta spread

Piyasa verileri

16 dakika önce guncellendi

14 May 26 2:001 Eki 26 3:59

Trendler

Sonuç24sOlasılık

Yalnızca sanal bakiye, gerçek para yokYatırım tavsiyesi değildir

Seçilen sonuç

Before Oct 1, 202637%

Tutar (USDT)

Kurallar

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Hacim trendi

$53

2 Tem14g veri28 Tem

İlgili Piyasalar

Will the FDA approve MDMA for PTSD?

₺0

Before Jan 1, 2027: 10%

KALSHI

Hantavirus pandemic in 2026?

₺5,3 Mn

Evet: 3%

POLYMARKET

# of views of MrBeast video day 3?

₺352,7 B

26-27M: 73%

POLYMARKET

New pandemic in 2026?

₺280,5 B

Evet: 9%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Bu konularda aktif

BitcoinBTC$63,480.41-3.05%

EthereumETH$1,881.56-4.27%

SolanaSOL$73.34-4.36%

DogecoinDOGE$0.07-4.13%

XRPXRP$1.06-4.87%

BNBBNB$564.93-1.71%

İlgili Haberler

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Kurallar

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals: